Results from this observational study indicate that a new switch molecule FHBM can accurately regulate the switchable dual-receptor CAR-T (sdCAR-T) cell activity in a time- and dose-dependent manner and sdCAR-T cells exert significant antitumor activity while releasing lower levels of cytokines for the cognate tumor cells expressing both MSLN and integrin αvβ3. Here, MSLN is linked to neoplasm.